What we are studying

Medical scientists have found that people with diabetes who take the drug Metformin have less age-related disease than those taking other treatments. In addition, metformin extends lifespan in some animal models of human disease. The purpose of this study is to see if taking Metformin causes changes in blood cells consistent with improved health and longevity in people who do not have diabetes. In this study Metformin will be compared to placebo. A placebo is a substance, like a sugar pill, that is not thought to have any effect on your disease or condition. In this study you will either receive the active study medication, Metformin or placebo which is not active.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 65 - 79

Eligibility Criteria

  • Must not have Type 2 Diabetes or take metformin already
  • Cannot have smoked in last year
  • Cannot have unintentional weight change in last year of 10 pounds or more
  • Cannot have kidney disease
  • Cannot have liver disease
  • Cannot have neurological or autoimmune disease

What is involved

  • Four total visits all including vitals
  • Physical performance testing
  • Cognitive testing
  • And blood draws. Participants will be asked to take Placebo for 12 weeks and Metformin for 12 weeks while in the study.


$60 in gift cards for all completed study visits after screening. If withdraw before completion, participants will receive $20 gift card for each completed study visit (not screening visit).

Contact Information

Study Coordinator
Erin Kennedy
Principal Investigator
Jingzhong Ding

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.